{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:13:19Z","timestamp":1782904399289,"version":"3.54.5"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["FEBS Open Bio"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Ras homolog gene family member V (RHOV) is an atypical Rho GTPase that participates in various important cellular processes. Although<jats:italic>RHOV<\/jats:italic>has been identified to play an oncogenic role in lung cancer and triple\u2010negative breast cancer, its role in other types of tumors remains unknown. In this study, we investigated the expression of<jats:italic>RHOV<\/jats:italic>in pan\u2010cancer analysis using The Cancer Genome Atlas (TCGA) and Gene\u2010Tissue Expression datasets.<jats:italic>RHOV<\/jats:italic>mRNA levels were dysregulated in several types of tumors.<jats:italic>RHOV<\/jats:italic>expression was identified as an independent prognostic factor in 7 of 33 types of tumors; however, the relationship varied according to tumor type. Higher<jats:italic>RHOV<\/jats:italic>expression was associated with a favorable prognosis in kidney renal cell carcinoma and prostate adenocarcinoma, for which<jats:italic>RHOV<\/jats:italic>expression was downregulated, whereas<jats:italic>RHOV<\/jats:italic>expression was associated with a poor prognosis for patients with adenoid cystic carcinoma, lung adenocarcinoma, pancreatic ductal adenocarcinoma, skin cutaneous melanoma, and uveal melanoma with upregulated<jats:italic>RHOV<\/jats:italic>expression. Furthermore,<jats:italic>RHOV<\/jats:italic>expression was associated with various clinicopathological parameters in these tumors.<jats:italic>RHOV<\/jats:italic>expression showed varied associations with different types of tumor\u2010infiltrating immune cells and demonstrated a potential impact on the response to immunotherapy depending on the cancer type. Additionally, functional enrichment analysis of<jats:italic>RHOV<\/jats:italic>\u2010related genes demonstrated a role in a wide range of developmental and immune\u2010related processes. This study provides valuable insights into the role of RHOV in pan\u2010cancer development, indicating its role as a tumor suppressor or oncogene according to the cancer type and tumor microenvironment.<\/jats:p>","DOI":"10.1002\/2211-5463.13698","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T13:06:53Z","timestamp":1692450413000},"page":"2124-2146","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic significance of the rho<scp>GTPase RHOV<\/scp>and its role in tumor immune cell infiltration: a comprehensive pan\u2010cancer analysis"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-2585","authenticated-orcid":false,"given":"Qin","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Oncology Jingzhou Hospital Affiliated to Yangtze University China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Oncology The Second People's Hospital of Jingmen China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12626"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1808"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.12.011"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.586414"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.605097"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5551036","article-title":"Pan\u2010cancer analysis of the prognostic and immunological role of HSF1: a potential target for survival and immunotherapy","volume":"2021","author":"Chen F","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857308"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.849592"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1044100"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954848"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-442-1_2"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/21541248.2017.1362495"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2476"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2007.07.031"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010125"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.4161\/sgtp.2.1.15229"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.2817"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2013.10.006"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.619013"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59939"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15783"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.06.006"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042563"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa407"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"}],"container-title":["FEBS Open Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/2211-5463.13698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T12:04:07Z","timestamp":1729944247000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1002\/2211-5463.13698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1002\/2211-5463.13698"],"URL":"https:\/\/doi.org\/10.1002\/2211-5463.13698","archive":["Portico"],"relation":{},"ISSN":["2211-5463","2211-5463"],"issn-type":[{"value":"2211-5463","type":"print"},{"value":"2211-5463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]},"assertion":[{"value":"2023-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}